Durect drug delivery news
Durect disclosed in its 1Q09 earnings that it reduced headcount across all functional areas by 41 (25%) in March to save cash. Durect is seeking a new partner for its Transdur-Sufentanil after Endo Pharmaceuticals Inc. (NASDAQ:ENDP, Chadds Ford, Pa.) returned rights to the transdermal sufentanil patch in February. The patch is in Phase II testing for pain. Durect's lead program is Remoxy. The high viscosity capsule formulation of oxycodone that uses Durect's Oradur technology is being co-developed by Pain Therapeutics Inc. (NASDAQ:PTIE, San Mateo, Calif.) and King Pharmaceuticals Inc. (NYSE:KG, Bristol, Tenn.). Pain Therapeutics received a complete response letter from FDA late last year for Remoxy (see BioCentury, Dec 15, 2008, & March 2, 2009). ...